Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Assets (2016 - 2026)

Akebia Therapeutics has reported Non-Current Assets over the past 11 years, most recently at $123.6 million for Q4 2025.

  • Quarterly Non-Current Assets rose 15.7% to $123.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $446.8 million through Dec 2025, up 2.82% year-over-year, with the annual reading at $123.6 million for FY2025, 15.7% up from the prior year.
  • Non-Current Assets was $123.6 million for Q4 2025 at Akebia Therapeutics, up from $105.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $280.8 million in Q2 2021 and troughed at $105.8 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $130.3 million (2023), against an average of $166.6 million.
  • Year-over-year, Non-Current Assets plummeted 41.0% in 2021 and then increased 15.7% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $258.2 million in 2021, then crashed by 33.82% to $170.9 million in 2022, then dropped by 27.69% to $123.6 million in 2023, then fell by 13.53% to $106.8 million in 2024, then rose by 15.7% to $123.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Assets are $123.6 million (Q4 2025), $105.8 million (Q3 2025), and $110.9 million (Q2 2025).